An international research effort has released one of the largest characterized collections of laboratory-grown models derived from human cancers. The National Institutes of Health announced on August 5 that the Human Cancer Models Initiative now includes 665 next-generation models spanning 25 cancer types, connected with a broader data set involving 2,780 donors.
Patient-derived models give researchers renewable material for studying how tumors grow and respond to experimental treatments. The collection includes organoids, which reproduce some of the cellular organization of organs, and neurospheres derived from brain cancers. Researchers can search by cancer type, treatment history, molecular features and available demographic or clinical information.
A central question is whether cells continue to resemble the original tumor after being removed from the body and grown for long periods. The collaboration examined 421 matched sets of tumors and models. NIH reported 97.8 percent agreement in genetic alterations, 95 percent concordance in epigenetic features and 92 percent similarity in RNA-expression patterns.
Those percentages describe molecular comparisons in the studied sample; they do not mean the models can predict treatment success with the same accuracy. Laboratory systems cannot reproduce every interaction among a tumor, immune system, blood supply and surrounding tissue. They are research tools rather than approved diagnostic tests or substitutes for clinical trials.
The collection nevertheless broadens the range of material available for preclinical work. NIH says it contains 522 models with detailed clinical data, 153 models of rare cancers and 71 derived from people of non-European ancestry. Existing repositories have often represented only a limited portion of cancer's genetic and clinical diversity.
The models are being distributed through the American Type Culture Collection, with related molecular and clinical data available through a searchable National Cancer Institute catalog. The principal study appeared in Nature alongside companion papers. Its near-term significance is greater access to standardized research material, not an immediate new treatment.